Global Pharmaceutical Contract Manufacturing Industry

  • June 2014
  • -
  • Global Industry Analysts
  • -
  • 185 pages

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 92 companies including many key and niche players such as -

AAIPharma Services Corporation
Aenova Group
Ajinomoto Althea, Inc.
Albany Molecular Research, Inc.
Dishman

Table Of Contents




I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Curtain Raiser II-1
Cost and Risk Containment Objectives Spur Outsourcing of
Biopharma Production II-2
Key Market Drivers II-2
Biopharma Contract Manufacturing Market Emerges from the
Recessionary Lull II-3
Table 1: Worldwide Funding for Biotech Projects by Geographic
Region (2012): Percentage Breakdown of Funding for North
America, Europe, and Rest of World (includes corresponding
Graph/Chart) II-3

Table 2: Worldwide Funding for Biotech Projects by Product
Development Phase (2012): Percentage Breakdown of Funding for
Products in Clinical Trial, Pre-Clinical Trial and
Commercialization Phases (includes corresponding Graph/Chart) II-4
Favorable Trends in the Pharma Industry Portend Bright Outlook
for the PCM Market II-4
Ballooning Global Population Offers Increased Growth
Opportunities II-4
Table 3: Top 25 Countries Worldwide in Terms of Population:
2007, 2010 and 2013 II-5
Surge in Generic Drugs to Benefit Pharmaceutical Contract
Manufacturers II-5
Table 4: Worldwide Annual Spending on Drugs by Category
(2011 and 2015): Percentage Breakdown of Dollar Sales for
Branded Drugs, Generic Drugs, and Others (includes
corresponding Graph/Chart) II-6
Increasing Consumption Drugs within Aging Population Boosts
Opportunities for PCM II-6
Table 5: Global Population Statistics for the 65+ Age Group
(2012) (includes corresponding Graph/Chart) II-7

Table 6: Elderly Population (65+ Years) as a % of Total
Population (2025) (includes corresponding Graph/Chart) II-8
Changing Healthcare Expenditure Trends to Spur Demand for
Contract Manufacturing of Generics II-8
Table 7: Healthcare Spending as a Percentage of GDP: 2012
(includes corresponding Graph/Chart) II-10
US and Europe Dominate Market, Asia-Pacific Lends Growth Momentum II-10
Major Changes Imperative to Capitalize on Brighter Future
Prospects II-11
Solid Dosage Form Retains Popularity among Pharma Contract
Manufacturers II-11
Injectable-Dose Formulations to Spearhead Growth of the PCM
Market II-12

2. MAJOR MARKET TRENDS and ISSUES II-14
Patent Expiries Augur Good Tidings for the PCM Market II-14
PCMs Gear Up to Tap Booming Biologics Market II-14
PCM Market for Vaccines Yet to Take Off II-14
Biotechnology Upstarts Spur Demand for Contract Manufacturing II-15
Vendor Switching- A Growing Concern for PCMs II-15
Marked Decrease Witnessed in Venture Capital Investment into
PCM Upstarts II-16
PCM Industry Gravitates Eastward, and Subsequently Leads to
Near-Shoring II-16
Adoption of Cutting-Edge Technologies to Radicalize PCM
Environment II-17
RABS technology II-17
Quality by Design II-18
Track and Trace Techniques II-18
Disposable Processing Techniques II-18
Upstream and Downstream Processes II-18
Process Analytical Technology II-19
Near Infrared Spectroscopy II-19
Increased Regulator Scrutiny: A Cause of Concern for the
Emerging Market PCMs II-19

3. COMPETITIVE LANDSCAPE II-20
PCM - A Highly Fragmented Industry Undergoing Consolidation II-20
Table 8: Worldwide Pharmaceutical Contract Manufacturing
Market by Leading Players (2013): Percentage Breakdown of
Value Sales for Catalent Pharma Solutions, DPx Holdings B.V.,
Famar Health Care Services, and Others (includes
corresponding Graph/Chart) II-20

Table 9: Worldwide Injectables Contract Manufacturing Market
by Leading Players (2013): Percentage Breakdown of Value
Sales for Baxter, Hospira, Vetter and Others (includes
corresponding Graph/Chart) II-20
PCMs Battle Fierce Competition and Commoditization II-20
Large Enterprises Edging Out Small-scale Players II-21
Competitive Pricing Pressure to Spur Consolidation II-21
Competition Heats Up in Injectables Market, PCMs Expand
Capabilities and Service Offerings II-22

4. SERVICE OVERVIEW II-23
Introduction II-23
Injectables (Injections, Vials, and IV solutions) II-23
Solid Dosage Forms (SDFs) (Tablets and Capsules) II-23
Liquid Dosage Forms (LDFs) (Syrups and Suspensions) II-24
An Insight into the Rise of Pharmaceutical Contract Manufacturing II-24
Investment Risks in Pharmaceutical Contract Manufacturing II-25
Quality Assurance Risk II-25
Drug Development Risk II-25
Acquisition Risk II-25
Client Dependency Risk II-25

5. RECENT INDUSTRY ACTIVITY II-26
Onyx Announces completion of API project with Neuronascent II-26
Meiji Holdings Buys Medreich Lifecare Limited II-26
Emilia Group Takes Over Pharma Pac LLC II-26
AMRI to Take Over Cedarburg Pharma II-26
AMRI to Acquire OsoBio Biopharmaceuticals Manufacturing II-26
Royal DSM’s DPP Merges with JLL Partners’ Pantheon, Giving
Rise to DPx Holdings B.V. II-26
Emergent BioSolutions Takes Over Cangene Corporation II-26
Dendreon Appoints PharmaCell as European CMO II-27
Ajinomoto Acquires Althea Technologies II-27
Aenova Group Merges with Haupt Pharma II-27
Kemwell Biopharma Takes Over Cirrus Pharmaceuticals II-27
Questcor Acquires BioVectra II-27
ICON Buys Cross Country Healthcare’s Clinical Trial Services
Division II-27
Columbia Laboratories Acquires Molecular Profiles II-27
EPS Corp Acquires Gleneagles CRC from IHH Healthcare II-27
Capsugel to Take Over Bend Research II-28
Gallus BioPharmaceutical Takes Over Laureate Biopharmaceutical II-28
PLI Holdings Acquires Pfanstiehl Laboratories II-28
DPT Laboratories Announce Integration With Confab II-28
Nordion Inks Contract Manufacturing Agreement with Navidea II-28
Unilife Receives Injectables Contract from Hikma II-28
NextPharma Technologies Expands Bielefeld Production Capacity
and Capabilities II-28
Fuji Pharma to Acquire OLIC from DKSH II-28
DSM Pharmaceutical Partners Almac Group II-28
Metrics Inc Introduces Generic Drug of Oxycodone HCl 5mg II-29
Patheon Completes Acquires Banner Pharmacaps II-29
PAREXEL International Acquires Liquent II-29
American Capital Acquires Cambridge Major II-29
Aenova Group Takes Over Euro Vital Pharma II-29
Althea Technologies Receives Contract from Pfenex II-29

6. FOCUS ON SELECT GLOBAL PLAYERS II-30
AAIPharma Services Corporation (US) II-30
Aenova Group (Germany) II-30
Haupt Pharma AG (Germany) II-30
Ajinomoto Althea, Inc. (US) II-31
Albany Molecular Research Inc. (US) II-31
Boehringer Ingelheim GmbH (Germany) II-32
Catalent Pharma Solutions, Inc. (US) II-32
Dishman (India) II-33
DPx Holdings B.V. (US) II-33
Famar Health Care Services (Greece) II-34
Hospira, Inc. (US) II-34
Jubilant Life Sciences Limited (India) II-34
Kemwell Biopharma Pvt. Ltd (India) II-35
Lonza Group Ltd. (Switzerland) II-35
NextPharma Technologies Holding Ltd (UK) II-36
Nipro Pharma Corporation (Japan) II-36
Recipharm AB (Sweden) II-37
Cobra Biologics Holding AB (Sweden) II-37

7. GLOBAL MARKET PERSPECTIVE II-38
Table 10: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Thousand for the Years 2013 through 2020 (includes
corresponding Graph/Chart) II-38

Table 11: World Historic Review for Pharmaceutical Contract
Manufacturing by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Thousand for the
Years 2006 through 2012 (includes corresponding Graph/Chart) II-39

Table 12: World 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Geographic Region - Percentage
Breakdown of Annual Revenues for US, Canada, Japan, Europe,
Asia-Pacific and Rest of World Markets for the Years 2006,
2014 and 2020 (includes corresponding Graph/Chart) II-40

Table 13: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing of Injectables
(Injections, Vials and Intravenous Solutions) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of
World Markets Independently Analyzed with Annual Revenue
Figures in US$ Thousand for the Years 2013 through 2020
(includes corresponding Graph/Chart) II-41

Table 14: World Historic Review for Pharmaceutical Contract
Manufacturing of Injectables (Injections, Vials and Intravenous
Solutions) by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Thousand for the Years 2006
through 2012 (includes corresponding Graph/Chart) II-42

Table 15: World 15-Year Perspective for Pharmaceutical
Contract Manufacturing of Injectables (Injections, Vials and
Intravenous Solutions) by Geographic Region - Percentage
Breakdown of Annual Revenues for US, Canada, Japan, Europe,
Asia-Pacific and Rest of World Markets for the Years 2006,
2014 and 2020 (includes corresponding Graph/Chart) II-43

Table 16: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing of Solid Dosage Forms
(Tablets and Capsules) by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Thousand for the
Years 2013 through 2020 (includes corresponding Graph/Chart) II-44

Table 17: World Historic Review for Pharmaceutical Contract
Manufacturing of Solid Dosage Forms (Tablets and Capsules) by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for the Years 2006 through
2012 (includes corresponding Graph/Chart) II-45

Table 18: World 15-Year Perspective for Pharmaceutical
Contract Manufacturing of Solid Dosage Forms (Tablets and
Capsules) by Geographic Region - Percentage Breakdown of
Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for the Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) II-46

Table 19: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing of Liquid and Semi-solid
Dosage Forms (Syrups, Suspensions, Gels, Creams and Ointments)
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for the Years 2013 through
2020 (includes corresponding Graph/Chart) II-47

Table 20: World Historic Review for Pharmaceutical Contract
Manufacturing of Liquid and Semi-solid Dosage Forms (Syrups,
Suspensions, Gels, Creams and Ointments) by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Thousand for the Years 2006 through 2012 (includes
corresponding Graph/Chart) II-48

Table 21: World 15-Year Perspective for Pharmaceutical
Contract Manufacturing of Liquid and Semi-solid Dosage Forms
(Syrups, Suspensions, Gels, Creams and Ointments) by Geographic
Region - Percentage Breakdown of Annual Revenues for US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
for the Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-49


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
US PCM Market Overview III-1
Competitive Landscape III-2
Strategic Corporate Developments III-2
Select Key Players III-4
B.Market Analytics III-7
Table 22: The US Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Dosage Form -
Injectables (Injections, Vials and Intravenous Solutions),
Solid Dosage Forms (Tablets and Capsules) and Liquid and
Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams and
Ointments) Independently Analyzed with Annual Revenue
Figures in US$ Thousand for the Years 2013 through 2020
(includes corresponding Graph/Chart) III-7

Table 23: The US Historic Review for Pharmaceutical Contract
Manufacturing by Dosage Form - Injectables (Injections,
Vials and Intravenous Solutions), Solid Dosage Forms (Tablets and
Capsules) and Liquid and Semi-solid Dosage Forms (Syrups,
Suspensions, Gels, Creams and Ointments) Independently
Analyzed with Annual Revenue Figures in US$ Thousand for the
Years 2006 through 2012 (includes corresponding Graph/Chart) III-8

Table 24: The US 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Dosage Form - Percentage Breakdown
of Annual Revenues for Injectables (Injections, Vials and
Intravenous Solutions), Solid Dosage Forms (Tablets and
Capsules) and Liquid and Semi-solid Dosage Forms (Syrups,
Suspensions, Gels, Creams and Ointments) for the Years 2006,
2014 and 2020 (includes corresponding Graph/Chart) III-9

2. CANADA III-10
A.Market Analysis III-10
Strategic Corporate Developments III-10
B.Market Analytics III-11
Table 25: Canadian Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Dosage Form -
Injectables (Injections, Vials and Intravenous Solutions),
Solid Dosage Forms (Tablets and Capsules) and Liquid and
Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams and
Ointments) Independently Analyzed with Annual Revenue
Figures in US$ Thousand for the Years 2013 through 2020
(includes corresponding Graph/Chart) III-11

Table 26: Canadian Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid and Semi-solid Dosage
Forms (Syrups, Suspensions, Gels, Creams and Ointments)
Independently Analyzed with Annual Revenue Figures in US$
Thousand for the Years 2006 through 2012 (includes
corresponding Graph/Chart) III-12

Table 27: Canadian 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Dosage Form - Percentage Breakdown
of Annual Revenues for Injectables (Injections, Vials and
Intravenous Solutions), Solid Dosage Forms (Tablets and
Capsules) and Liquid and Semi-solid Dosage Forms (Syrups,
Suspensions, Gels, Creams and Ointments) for the Years 2006,
2014 and 2020 (includes corresponding Graph/Chart) III-13

3. JAPAN III-14
A.Market Analysis III-14
Strategic Corporate Development III-14
Nipro Pharma Corporation - A Key Japanese Player III-14
B.Market Analytics III-15
Table 28: Japanese Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Dosage Form -
Injectables (Injections, Vials and Intravenous Solutions),
Solid Dosage Forms (Tablets and Capsules) and Liquid and
Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams and
Ointments) Independently Analyzed with Annual Revenue
Figures in US$ Thousand for the Years 2013 through 2020
(includes corresponding Graph/Chart) III-15

Table 29: Japanese Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid and Semi-solid Dosage
Forms (Syrups, Suspensions, Gels, Creams and Ointments)
Independently Analyzed with Annual Revenue Figures in US$
Thousand for the Years 2006 through 2012 (includes
corresponding Graph/Chart) III-16

Table 30: Japanese 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Dosage Form - Percentage Breakdown
of Annual Revenues for Injectables (Injections, Vials and
Intravenous Solutions), Solid Dosage Forms (Tablets and
Capsules) and Liquid and Semi-solid Dosage Forms (Syrups,
Suspensions, Gels, Creams and Ointments) for the Years 2006,
2014 and 2020 (includes corresponding Graph/Chart) III-17

4. EUROPE III-18
A.Market Analysis III-18
European PCM Market Caught in Eurodebt Doldrums III-18
Injectables Segment Offers Promising Potential III-18
Mammalian Cell Technology Dominates PCM Market III-19
Competitive Scenario III-19
Overview of Select Markets III-19
Germany III-19
Russia III-19
Strategic Corporate Developments III-20
Select Key Players III-21
B.Market Analytics III-24
Table 31: European Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Dosage Form -
Injectables (Injections, Vials and Intravenous Solutions),
Solid Dosage Forms (Tablets and Capsules) and Liquid and
Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams and
Ointments) Independently Analyzed with Annual Revenue
Figures in US$ Thousand for the Years 2013 through 2020
(includes corresponding Graph/Chart) III-24

Table 32: European Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid and Semi-solid Dosage
Forms (Syrups, Suspensions, Gels, Creams and Ointments)
Independently Analyzed with Annual Revenue Figures in US$
Thousand for the Years 2006 through 2012 (includes
corresponding Graph/Chart) III-25

Table 33: European 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Dosage Form - Percentage Breakdown
of Annual Revenues for Injectables (Injections, Vials and
Intravenous Solutions), Solid Dosage Forms (Tablets and
Capsules) and Liquid and Semi-solid Dosage Forms (Syrups,
Suspensions, Gels, Creams and Ointments) for the Years 2006,
2014 and 2020 (includes corresponding Graph/Chart) III-26

5. ASIA-PACIFIC III-27
A.Market Analysis III-27
Favorable Government Policies Transform China and India into
PCM Hubs III-27
Competitive Scenario III-27
Overview of Select Regional Markets III-28
China III-28
Outsourcing Industry Bogged Down by Recession III-28
India III-28
Indian PCMs Battle Soaring Costs III-29
Strategic Corporate Developments III-29
Select Key Players III-29
B.Market Analytics III-31
Table 34: Asia-Pacific Recent Past, Current and Future
Analysis for Pharmaceutical Contract Manufacturing by Dosage
Form - Injectables (Injections, Vials and Intravenous
Solutions), Solid Dosage Forms (Tablets and Capsules) and
Liquid and Semi-solid Dosage Forms (Syrups, Suspensions, Gels,
Creams and Ointments) Independently Analyzed with Annual
Revenue Figures in US$ Thousand for the Years 2013 through
2020 (includes corresponding Graph/Chart) III-31

Table 35: Asia-Pacific Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid and Semi-solid Dosage
Forms (Syrups, Suspensions, Gels, Creams and Ointments)
Independently Analyzed with Annual Revenue Figures in US$
Thousand for the Years 2006 through 2012 (includes
corresponding Graph/Chart) III-32

Table 36: Asia-Pacific 15-Year Perspective for
Pharmaceutical Contract Manufacturing by Dosage Form -
Percentage Breakdown of Annual Revenues for Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid and Semi-solid Dosage
Forms (Syrups, Suspensions, Gels, Creams and Ointments) for
the Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-33

6. REST OF WORLD III-34
Market Analysis III-34
Table 37: Rest of World Recent Past, Current and Future
Analysis for Pharmaceutical Contract Manufacturing by Dosage
Form - Injectables (Injections, Vials and Intravenous
Solutions), Solid Dosage Forms (Tablets and Capsules) and
Liquid and Semi-solid Dosage Forms (Syrups, Suspensions, Gels,
Creams and Ointments) Independently Analyzed with Annual
Revenue Figures in US$ Thousand for the Years 2013 through
2020 (includes corresponding Graph/Chart) III-34

Table 38: Rest of World Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid and Semi-solid Dosage
Forms (Syrups, Suspensions, Gels, Creams and Ointments)
Independently Analyzed with Annual Revenue Figures in US$
Thousand for the Years 2006 through 2012 (includes
corresponding Graph/Chart) III-35

Table 39: Rest of World 15-Year Perspective for
Pharmaceutical Contract Manufacturing by Dosage Form -
Percentage Breakdown of Annual Revenues for Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid and Semi-solid Dosage
Forms (Syrups, Suspensions, Gels, Creams and Ointments) for
the Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-36


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 92

The United States (34)
Canada (3)
Japan (4)
Europe (33)
- France (3)
- Germany (8)
- The United Kingdom (9)
- Italy (3)
- Rest of Europe (10)
Asia-Pacific (Excluding Japan) (18)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cance ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...


1 Companies

Company Profiles

Volcano Corp.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.